Several other research firms have also issued reports on GXI. Hauck & Aufhaeuser set a €60.00 ($69.77) target price on shares of Gerresheimer and gave the company a sell rating in a report on Monday, October 8th. Goldman Sachs Group set a €70.00 ($81.40) target price on shares of Gerresheimer and gave the company a neutral rating in a report on Monday, June 18th. DZ Bank restated a buy rating on shares of Gerresheimer in a report on Thursday, July 12th. HSBC set a €67.00 ($77.91) target price on shares of Gerresheimer and gave the company a neutral rating in a report on Monday, July 16th. Finally, Kepler Capital Markets set a €65.00 ($75.58) target price on shares of Gerresheimer and gave the company a sell rating in a report on Thursday, July 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of €70.75 ($82.27).
GXI stock opened at €59.75 ($69.48) on Friday. Gerresheimer has a 12-month low of €59.97 ($69.73) and a 12-month high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Recommended Story: Discount Rate
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.